Therapy was delivered to animals after the surgical removal of primary tumors, once lymph node metastases were confirmed by BLI. Treatment was initiated on the week of tumor removal. The therapeutic protocol consisted of concurrent injections of MN-anti-miR10b or MN-scr-miR intravenously, 15 mg kg−1 as iron, 10 mg kg−1 as LNA) and low-dose doxorubicin (i.p. 4 mg kg−1, Sigma, St. Louis, MO) for the following treatment groups were used: Group 1 - PBS only (n = 2), Group 2 - MN-scr-miR without doxorubicin (n = 6), Group 3 -MN-scr-miR with doxorubicin (n = 10), Group 4 -MN-anti-miR10b only (n = 7), and Group 5 -MN-scr-miR10b with doxorubicin (n = 10). Therapy was administered weekly until the disappearance of BLI-visible metastasis (4 weeks to all mice in Group 5, 12 weeks to all the mice in Groups 1 to 4). All mice were monitored weekly by bioluminescence imaging to assess metastatic burden for a maximum of 20 weeks after the first treatment or until animals become moribund. Mouse body weight was monitored before each imaging session.
Doxorubicin
Manufactured by Merck Group
Sourced in United States, Germany, United Kingdom, France, China, India, Italy, Poland, Macao, Japan, Sao Tome and Principe, Canada, Spain, Brazil, Australia, Belgium, Switzerland, Singapore, Israel
Doxorubicin is a cytotoxic medication that is commonly used in the treatment of various types of cancer. It functions as an anthracycline antibiotic, which works by interfering with the DNA replication process in cancer cells, leading to their destruction. Doxorubicin is widely used in the management of different malignancies, including leukemia, lymphoma, and solid tumors.
Automatically generated - may contain errors
Lab products found in correlation
Cisplatin, by Merck Group (159 mentions)
Fetal bovine serum (fbs), by Thermo Fisher Scientific (123 mentions)
Paclitaxel, by Merck Group (118 mentions)
Dimethyl sulfoxide (dmso), by Merck Group (118 mentions)
Etoposide, by Merck Group (108 mentions)
Penicillin streptomycin, by Thermo Fisher Scientific (50 mentions)
Verapamil, by Merck Group (43 mentions)
Vincristine, by Merck Group (40 mentions)
Penicillin, by Thermo Fisher Scientific (35 mentions)
Streptomycin, by Thermo Fisher Scientific (34 mentions)
Cycloheximide (chx), by Merck Group (33 mentions)
Dulbecco modified eagle medium (dmem), by Thermo Fisher Scientific (33 mentions)
Docetaxel, by Merck Group (31 mentions)
Mitoxantrone, by Merck Group (30 mentions)
5 fluorouracil, by Merck Group (30 mentions)
Propidium iodide, by Merck Group (29 mentions)
Gemcitabine, by Merck Group (28 mentions)
Methyl thiazolyl tetrazolium (mtt), by Merck Group (27 mentions)
Fetal bovine serum (fbs), by Merck Group (27 mentions)
Vinblastine, by Merck Group (26 mentions)
1 339 protocols using doxorubicin
1
Nanomedicine Therapy for Metastatic Cancer
2
Doxorubicin-Induced Cardiotoxicity in Mice
3
Cell culture and treatment conditions
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
NB4 cell lines were cultured in RPMI 1640 (HEPES-containing) medium (Sigma-Aldrich, St. Louis, MO, USA), while MCF-7 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich) supplemented with 10% (v/v) foetal bovine serum (Gibco, Paisley, Scotland), 2 mM L-glutamine, 1% (v/v) 100 U/mL penicillin-streptomycin, and 1% sodium pyruvate solution (10 mg/mL) (Sigma-Aldrich) at 37 °C in 5% CO2. All cell lines were periodically tested for mycoplasma contamination.
The NB4 cells were treated with 1 μM all-trans retinoic acid (ATRA) (Sigma-Aldrich) alone or in combination with 0.5 μM or 2.0 μM arsenic trioxide (ATO) for 5 days.
MCF-7 cells were treated with 1 µg/mL doxorubicin (Sigma Aldrich), 1 μM ATRA, 1 μM ATRA + 1 µg/mL doxorubicin, or 1 µg/mL doxorubicin + 2.0 μM ATO for 3 and 5 days.
Human monocytes were treated with 2.0 μM ATO, 2.0 μM calpain inhibitor, 5 nM macrophage colony-stimulating factor (MCSF), 5 nM MCSF + 2.0 μM ATO, 5 nM MCSF + 2.0 μM ATO + 2.0 μM calpain inhibitor, or 5 nM MCSF + 2.0 μM calpain inhibitor for 3 and 5 days.
The NB4 cells were treated with 1 μM all-trans retinoic acid (ATRA) (Sigma-Aldrich) alone or in combination with 0.5 μM or 2.0 μM arsenic trioxide (ATO) for 5 days.
MCF-7 cells were treated with 1 µg/mL doxorubicin (Sigma Aldrich), 1 μM ATRA, 1 μM ATRA + 1 µg/mL doxorubicin, or 1 µg/mL doxorubicin + 2.0 μM ATO for 3 and 5 days.
Human monocytes were treated with 2.0 μM ATO, 2.0 μM calpain inhibitor, 5 nM macrophage colony-stimulating factor (MCSF), 5 nM MCSF + 2.0 μM ATO, 5 nM MCSF + 2.0 μM ATO + 2.0 μM calpain inhibitor, or 5 nM MCSF + 2.0 μM calpain inhibitor for 3 and 5 days.
4
Comparative Study of ICR Mouse Sources
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Male ICR mice were obtained from three different sources. Korl:ICR were kindly provided by the Department of Laboratory Animal Resources in the National Institute of Food and Drug Safety Evaluation (NIFDS, Cheongju, Korea). The other two groups of ICR stocks were purchased from different vendors located in the United States (referred A: ICR) and Japan (referred B: ICR). The use of animals was in compliance with the guidelines established and approved by the Institutional Animal Care and Use Committee in Pusan National University (PNU-2016-1236). Animals were acclimated to temperature (22±2℃) and humidity (55±5%) controlled rooms with a 12-h light/dark cycle for 1 week prior to use. All mice were provided with ad libitum access to standard irradiated chow diet (Samtako Inc., Osan, Korea) consisting of moisture (12.5%), crude protein (25.43%), crude fat (6.06%), crude fiber (3.9%), crude ash (5.31%), calcium (1.14%), and phosphorus (0.99%) and water. Alterations in body weight were measured using an electronic balance (Mettler Toledo, Greifensee, Switzerland) once a week according to the MFDS guideline. Doxorubicin-treated mice received a single intraperitoneal injection of 20 mg/kg of Doxorubicin (Sigma Aldrich, St. Louis, MO, USA) and samples were collected 4 days after Doxorubicin administration
5
Generation of Doxorubicin Resistant Breast Cancer Cell Line
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Doxorubicin was purchased from Sigma-Aldrich (St. Louis, MO, USA) and dissolved in dimethyl sulfoxide (DMSO) at a stock concentration of 30 mM. To generate the acquired Doxorubicin resistant cell line, MCF-7 cells seeded at 30–50% confluency were exposed to 6 pulses of Doxorubicin (Sigma-Aldrich, St. Louis, MO, USA) at its half maximal inhibitory concentration (IC50) in complete RPMI supplemented with 10% FBS and 1% PS for 24 h each followed by a recovery period of one week at 37 °C with 5% CO2. Control cells were maintained alongside in complete RPMI containing DMSO. Doxorubicin resistance was assessed by determination of Doxorubicin IC50 wherein cells seeded at 5x103 cells/well in 96-well microtiter plates were exposed to increasing concentrations of Doxorubicin prepared in complete media for 72 h at 37 °C with 5% CO2. Cell viability was quantified by 10% AlamarBlue (Life Technologies, Carlsbad, CA, USA) according to the manufacturer’s protocol. Fluorescence was determined using a microplate reader (Infinite 200, Tecan, Mannedorf, Zurich, Switzerland) at 560nm and 590nm for excitation and emission respectively. IC50 values were tabulated using Graphpad Prism 5 software (GraphPad Software, Inc., San Diego, CA, USA).
6
Flavonoids and Doxorubicin Cytotoxicity Evaluation
7
Evaluation of Compound Solubility and Potency
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The following compounds were tested in this study (all purchased from Sigma-Aldrich): ATRA, 5′-fluorouracil, forskolin, doxorubicin, dexamethasone, SDS, and penicillin-G. SDS and penicillin-G served as the positive and negative controls, respectively, for this assay. The compounds were prepared in either (maximum final concentration in parentheses): 1% dimethyl sulfoxide (DMSO, Sigma-Aldrich) for ATRA (166.42 μM) and dexamethasone (509.60 μM); or PBS (pH~7.4, Sigma-Aldrich) for doxorubicin (100 μM), 5′-fluorouracil (256 μM), forskolin (10 μM), SDS (625 μM), and penicillin-G (5.98 mM). Vehicle controls were exposed to the solvent alone and tested for each compound, with its analysis being conducted separately from that of other vehicle controls with the same solvent.
8
Cytotoxic Agents in Cancer Treatment
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Doxorubicin (Sigma, St. Louis, USA), 5-aza-2′-deoxycytidine (decitabine/5-AZA-CdR, Sigma), azacitidine (Celgene, Summit, NJ, USA), cisplatin (Sigma), gemcitabine (Sigma), etoposide (Sigma), docetaxel (Sigma), paclitaxel (Sigma), vinblastine (Sigma), panobinostat (Sigma), vorinostat (Sigma) and bortezomib (Sigma) were added from a stock solution to the 10% serum-containing RPMI medium (Gibco, Waltham, MA, USA). Doxorubicin, etoposide, docetaxel, paclitaxel, vinblastine, panobinostat, vorinostat and bortezomib were dissolved in dimethyl sulfoxide (DMSO; Sigma), cisplatin was dissolved in 10% DMSO (Sigma) in 10% serum-containing RPMI, and 5-AZA-CdR, azacitidine and gemcitabine were dissolved in distilled water. Dose calculation was based on human dosages and previous publications [10 (link)].
9
Cytotoxicity Assay of Chemotherapeutics
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
A volume of 100 μL per well of cells in supplemented media were incubated at 37°C and 5% CO2 with doxorubicin (Sigma-Aldrich, Milwaukee, WI, USA), idarubicin (Sigma-Aldrich), BEZ-235 (provided by Novartis, Inc.), or selumetinib (ChemieTek, Indianapolis, IN, USA). Each compound was plated using a nine-point logarithmic concentration scale ranging from 15 nM to 100 μM. Stock solutions of doxorubicin and idarubicin (10 mM) were prepared in water while stock solutions of BEZ-235 and selumetinib (25 mM and 75 mM, respectively) were prepared in 100% dimethyl sulfoxide (DMSO) (Sigma-Aldrich). Subsequent dilutions and controls were prepared to account for the inclusion of water or DMSO in the stock solution.
10
Evaluating Cell Survival Fraction
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
To treat MCF10A-shLuc and MCF10A-shDST cells with Tet and Doxorubicin, cells were seeded to reach 20% confluency at 24 hours post-seeding and then treated with 400 ng/ml Tet (Sigma-Aldrich; T7660). After 48 hours, media containing 400 ng/ml Tet and 250 nM of Doxorubicin (Sigma-Aldrich; D1515) dissolved in PBS was applied for an additional 24 hours. 1 000 cells per well were then seeded in 6 well plates in triplicates and incubated for 9 days. Medium was replaced every 3 days with fresh media containing Tet. At the end of 9 days, colonies were fixed with 3.5% paraformaldehyde and stained with 0.005% crystal violet diluted in 20% ethanol solution. Colonies were counted manually. Percent surviving fraction was calculated as – (Number of colonies formed/Number of cells seeded*Plating Efficiency)79 (link).
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!